Search Results - "Humanized/administration"
-
1
Authors: et al.
Source: New England Journal of Medicine. 393:37-50
Subject Terms: Adult, Male, Antibodies, Monoclonal, Humanized / adverse effects, Antibodies, Monoclonal, Humanized / administration & dosage, Young Adult, Chemotherapy, Adjuvant / methods, B7-H1 Antigen / analysis, B7-H1 Antigen / antagonists & inhibitors, Humans, Neoadjuvant Therapy / adverse effects, Antineoplastic Agents, Immunological / administration & dosage, Antineoplastic Agents, Immunological / adverse effects, Aged, Aged, 80 and over, Head and Neck Neoplasms / mortality, Head and Neck Neoplasms / pathology, Squamous Cell Carcinoma of Head and Neck / pathology, Middle Aged, Head and Neck Neoplasms / drug therapy, Neoadjuvant Therapy / methods, Progression-Free Survival, Squamous Cell Carcinoma of Head and Neck / surgery, Intention to Treat Analysis, B7-H1 Antigen / metabolism, Treatment Outcome, Head and Neck Neoplasms / surgery, Squamous Cell Carcinoma of Head and Neck / drug therapy, Female, Chemotherapy, Adjuvant / adverse effects, Squamous Cell Carcinoma of Head and Neck / mortality
File Description: application/pdf
-
2
Authors: et al.
Source: Headache
Headache, vol. 65, no. 7, pp. 1134-1147Subject Terms: Research Submission, Headache Impact Test‐6, drug holiday, chronic and episodic migraine, Humans, Migraine Disorders/drug therapy, Female, Male, Adult, Antibodies, Monoclonal, Humanized/pharmacology, Antibodies, Monoclonal, Humanized/therapeutic use, Antibodies, Monoclonal, Humanized/administration & dosage, Quality of Life, Middle Aged, Calcitonin Gene-Related Peptide Receptor Antagonists/pharmacology, Calcitonin Gene-Related Peptide Receptor Antagonists/therapeutic use, Calcitonin Gene-Related Peptide Receptor Antagonists/administration & dosage, Switzerland, Prospective Studies, Patient Reported Outcome Measures, Aged, Retrospective Studies, Impact of Migraine on Partners and Adolescent Children, medication overuse, monthly migraine days
File Description: application/pdf
-
3
Authors: et al.
Contributors: et al.
Source: Annals of Oncology. 36:277-284
Subject Terms: Male, Adult, mismatch repair deficient, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, DNA Mismatch Repair, Antibodies, Antineoplastic Agents, Immunological, Immunological/therapeutic use, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Humans, Aged, Aged, 80 and over, Bevacizumab/administration & dosage, microsatellite instability high, metastatic colorectal cancer, Colorectal Neoplasms/drug therapy, Hematology, Middle Aged, Progression-Free Survival, Bevacizumab, Oncology, Humanized/administration & dosage, Microsatellite Instability, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, pembrolizumab, Colorectal Neoplasms, Follow-Up Studies
File Description: application/pdf
-
4
Authors:
Source: Journal of Drugs in Dermatology. 24:242-245
Subject Terms: Adult, Male, Interleukins, Phase II as Topic, Dermatologic Agents/administration & dosage, Middle Aged, Antibodies, Monoclonal, Humanized, Symptom Flare Up, Antibodies, Treatment Outcome, Monoclonal, Psoriasis/drug therapy, Humanized/administration & dosage, Humans, Psoriasis, Clinical Trials, Female, Dermatologic Agents
-
5
Authors: et al.
Contributors: et al.
Source: Nat Med
NATURE MEDICINESubject Terms: atezolizumab, Male, Adult, INCREASES, Medizin, Oncologie, VACCINE, CD8-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes/immunology, Antibodies, Monoclonal, Humanized, THERAPY, Neoplasms/pathology, Sciences de la santé humaine, Article, Antigens, Neoplasm, Neoplasms, Neoplasms/immunology, Antineoplastic Combined Chemotherapy Protocols, Medicine and Health Sciences, Journal Article, Humans, HETEROGENEITY, Human health sciences, Antigens, Neoplasm/immunology, Aged, Aged, 80 and over, Cancer och onkologi, Biochemistry, Genetics and Molecular Biology (all), CTLA-4 BLOCKADE, Biology and Life Sciences, Middle Aged, CANCER, CD8-Positive T-Lymphocytes/drug effects, Neoplasms/drug therapy, Antibodies, Monoclonal, Humanized/therapeutic use, Oncology, Cancer and Oncology, CELLS, Immunotherapy/methods, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Immunotherapy, Antibodies, Monoclonal, Humanized/administration & dosage
File Description: application/pdf
Access URL: https://pubmed.ncbi.nlm.nih.gov/39762422
https://dspace.library.uu.nl/handle/1874/460017
https://hdl.handle.net/2268/328378
https://doi.org/10.1038/s41591-024-03334-7
https://biblio.ugent.be/publication/01JQNPTCN4PKBW9FWBK5R9XS5W/file/01JQNVF8RNY77SZSGTDWKT746H
http://doi.org/10.1038/s41591-024-03334-7
http://hdl.handle.net/1854/LU-01JQNPTCN4PKBW9FWBK5R9XS5W
https://biblio.ugent.be/publication/01JQNPTCN4PKBW9FWBK5R9XS5W
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-555329
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85214121815
https://www.ncbi.nlm.nih.gov/pubmed/39762422
https://doi.org/10.1038/s41591-024-03334-7 -
6
Authors: et al.
Source: Indian J Ophthalmol
Indian Journal of Ophthalmology, Vol 72, Iss 12, Pp 1786-1794 (2024)Subject Terms: Male, Vascular Endothelial Growth Factor A, 0301 basic medicine, brolucizumab, Fundus Oculi, Optical Coherence/methods, Visual Acuity, India, Angiogenesis Inhibitors, Fluorescein Angiography/methods, Antibodies, Monoclonal, Humanized, Antibodies, Humanized/administration & dosage therapeutic use, 03 medical and health sciences, 0302 clinical medicine, Angiogenesis Inhibitors/administration & dosage, Monoclonal, 80 and over, Vascular Endothelial Growth Factor A/antagonists & inhibitors, Humans, Fluorescein Angiography, Tomography, Retrospective Studies, Aged, Aged, 80 and over, Wet Macular Degeneration/drug therapy diagnosis physiopathology, vascular endothelial growth factor, neovascular amd, RE1-994, Middle Aged, India/epidemiology, Ophthalmology, Treatment Outcome, Intravitreal Injections, Wet Macular Degeneration, Original Article, Female, Tomography, Optical Coherence, Follow-Up Studies
-
7
Authors: et al.
Source: Clin Cancer Res
Subject Terms: Male, Adult, Lung Neoplasms/genetics, Lung Neoplasms, Adoptive, Adoptive/adverse effects, Pilot Projects, HLA-A2 Antigen/genetics, Antibodies, Monoclonal, Humanized, Cancer Vaccines, Immunotherapy, Adoptive, Antibodies, Clinical Trials: Immunotherapy, Antigens, Neoplasm, Carcinoma, Non-Small-Cell Lung, Monoclonal, HLA-A2 Antigen, Medicine and Health Sciences, 80 and over, Humans, Antigens, Membrane Proteins/genetics, Non-Small-Cell Lung, Humanized, Aged, Neoplasm Staging, Non-Small-Cell Lung/genetics, Aged, 80 and over, Neoplasm/genetics, Cancer Vaccines/administration & dosage, Carcinoma, ICTS (Institute of Clinical and Translational Sciences), Membrane Proteins, Middle Aged, Treatment Outcome, Humanized/administration & dosage, Neoplasm, Female, Immunotherapy
File Description: application/pdf
-
8
Authors: et al.
Source: Clin Cancer Res
Subject Terms: Male, Pancreatic Neoplasms/pathology, Oncologie, Carcinoma, Pancreatic Ductal/drug therapy, Deoxycytidine, ACTIVATION, Deoxycytidine/analogs & derivatives, Pancreatic Neoplasms/drug therapy, Antineoplastic Combined Chemotherapy Protocols, Paclitaxel/adverse effects, Human health sciences, Neoplasm Metastasis, Aged, 80 and over, CHEMORESISTANCE, Carcinoma, Pancreatic Ductal/immunology, Medicine (all), Middle Aged, Treatment Outcome, Oncology, Antibodies, Monoclonal, Humanized/adverse effects, Female, Pancreatic Neoplasms/immunology, Life Sciences & Biomedicine, Albumins/administration & dosage, Antibodies, Monoclonal, Humanized/administration & dosage, Carcinoma, Pancreatic Ductal, Adult, Paclitaxel, Clinical Trials: Targeted Therapy, Carcinoma, Pancreatic Ductal/pathology, Antibodies, Monoclonal, Humanized, Sciences de la santé humaine, POOR-PROGNOSIS, Paclitaxel/administration & dosage, 3211 Oncology and carcinogenesis, Albumins, Biomarkers, Tumor, Pancreatic Neoplasms/mortality, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Deoxycytidine/administration & dosage, Aged, Albumins/adverse effects, Science & Technology, Antineoplastic Combined Chemotherapy Protocols/adverse effects, IL1RAP protein, human, 3202 Clinical sciences, 130-nm albumin-bound paclitaxel, Gemcitabine, Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Interleukin-1 Receptor Accessory Protein, Deoxycytidine/therapeutic use
-
9
Authors: et al.
Contributors: et al.
Source: Fürstenau, M, Kater, A P, Robrecht, S, von Tresckow, J, Zhang, C, Gregor, M, Thornton, P, Staber, P B, Tadmor, T, Lindström, V, Juliusson, G, Janssens, A, Levin, M-D, da Cunha-Bang, C, Schneider, C, Goldschmidt, N, Vandenberghe, E, Rossi, D, Benz, R, Nösslinger, T, Heintel, D, Poulsen, C B, Christiansen, I, Frederiksen, H, Enggaard, L, Posthuma, E F M, Issa, D E, Visser, H P J, Bellido, M, Kutsch, N, Dürig, J, Stehle, A, Vöhringer, M, Böttcher, S, Schulte, C, Simon, F, Fink, A-M, Fischer, K, Holmes, E E, Kreuzer, K-A, Ritgen, M, Brüggemann, M, Tausch, E, Stilgenbauer, S, Hallek, M, Niemann, C U & Eichhorst, B 2024, 'First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial', The Lancet Oncology, vol. 25, no. 6, pp. 744-759. https://doi.org/10.1016/S1470-2045(24)00196-7
Fuerstenau, M, Kater, A P, Robrecht, S, von Tresckow, J, Zhang, C, Gregor, M, Thornton, P, Staber, P B, Tadmor, T, Lindstroem, V, Juliusson, G, Janssens, A, Levin, M-D, Cunha-Bang, C, Schneider, C, Goldschmidt, N, Vandenberghe, E, Rossi, D, Benz, R, Noesslinger, T, Heintel, D, Poulsen, C B, Christiansen, I, Frederiksen, H, Enggaard, L, Posthuma, E F M, Issa, D E, Visser, H P J, Bellido, M, Kutsch, N, Duerig, J, Stehle, A, Voehringer, M, Boettcher, S, Schulte, C, Simon, F, Fink, A-M, Fischer, K, Holmes, E E, Kreuzer, K-A, Ritgen, M, Brueggemann, M, Tausch, E, Stilgenbauer, S, Hallek, M, Niemann, C U & Eichhorst, B 2024, ' First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13) : 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial ', Lancet Oncology, vol. 25, no. 6, pp. 744-759 . https://doi.org/10.1016/S1470-2045(24)00196-7Subject Terms: Male, Medizin, Piperidines/administration & dosage, Rituximab/administration & dosage, Cyclophosphamide/administration & dosage, Vidarabine/analogs & derivatives, Piperidines, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Chronic, Sulfonamides, Leukemia, Ibrutinib, Heterocyclic/administration & dosage, Middle Aged, Lymphocytic, Progression-Free Survival, 3. Good health, Bendamustine, Humanized/administration & dosage, Female, Immunotherapy, Cancers, Rituximab, Vidarabine, Antibodies, Monoclonal, Humanized/administration & dosage, Adult, Guidelines, B-Cell/drug therapy, Antibodies, Monoclonal, Humanized, Antibodies, Bridged Bicyclo Compounds, Obinutuzumab, Humans, Pyrimidines/administration & dosage, Cyclophosphamide, Aged, Sulfonamides/administration & dosage, Acalabrutinib, Adenine, Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy, Pyrazoles/administration & dosage, Bridged Bicyclo Compounds, Heterocyclic, Leukemia, Lymphocytic, Chronic, B-Cell, Bridged Bicyclo Compounds, Heterocyclic/administration & dosage, Pyrimidines, Pyrazoles, Chlorambucil, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Adenine/analogs & derivatives, Cll, Follow-Up Studies
File Description: application/pdf
Access URL: https://pubmed.ncbi.nlm.nih.gov/38821083
https://vbn.aau.dk/ws/files/718022411/F_rstenau_et_al._2024_._First-line_venetoclax_combinations_versus_chemoimmunotherapy_in_fit_patients_with_chronic_lymphocytic_leukaemia_GAIA-CLL13_-_4-year_follow-up_from_a_multicentre_open-label_randomised_phase_3_trial.pdf
https://vbn.aau.dk/da/publications/94b2c096-a230-4cfb-b1cb-3f1e21048b8d
https://doi.org/10.1016/S1470-2045(24)00196-7
http://www.scopus.com/inward/record.url?scp=85194085374&partnerID=8YFLogxK
https://research.rug.nl/en/publications/54e23617-72a7-4e84-a971-484f9776d6b5
https://doi.org/10.1016/S1470-2045(24)00196-7
https://hdl.handle.net/11370/54e23617-72a7-4e84-a971-484f9776d6b5
https://pure.amsterdamumc.nl/en/publications/6c072122-c40d-4938-b051-ee450f59a5c9
https://doi.org/10.1016/S1470-2045(24)00196-7
http://hdl.handle.net/10138/576618
https://curis.ku.dk/ws/files/460526731/1-s2.0-S1470204524001967-main.pdf
https://portal.findresearcher.sdu.dk/da/publications/cdc040d1-38d0-4dd9-b810-60b242058f6d
https://doi.org/10.1016/S1470-2045(24)00196-7
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85194085374
https://doi.org/10.1016/s1470-2045(24)00196-7
https://www.ncbi.nlm.nih.gov/pubmed/38821083 -
10
Authors: et al.
Source: Acta Neurol Belg
Subject Terms: Male, Adult, ddc:610, Dose-Response Relationship, Drug, Migraine Disorders, Dose-Response Relationship, Drug [MeSH], Female [MeSH], Real-world, Aged [MeSH], Adult [MeSH], Humans [MeSH], Treatment Outcome [MeSH], Antibodies, Monoclonal, Humanized/administration, Retrospective Studies [MeSH], Middle Aged [MeSH], Calcitonin Gene-Related Peptide Receptor Antagonists/administration, Original Article, Male [MeSH], Preventive medication, Erenumab, Antibodies, Monoclonal, Humanized/therapeutic use [MeSH], Young Adult [MeSH], Migraine Disorders/drug therapy [MeSH], Migraine, Middle Aged, Antibodies, Monoclonal, Humanized, 3. Good health, Young Adult, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, Calcitonin Gene-Related Peptide Receptor Antagonists, Humans, Female, Retrospective Studies, Aged
File Description: application/pdf
-
11
Authors: et al.
Source: J Neurol
Subject Terms: Male, Adult, ddc:610, Original Communication, Middle Aged, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Multiple Sclerosis, Relapsing-Remitting, 0302 clinical medicine, Quality of Life, Humans, Female, Prospective Studies, Longitudinal Studies, Female [MeSH], Follow-Up Studies [MeSH], Adult [MeSH], Humans [MeSH], Prospective Studies [MeSH], Ofatumumab, Longitudinal Studies [MeSH], Antibodies, Monoclonal, Humanized/administration, Middle Aged [MeSH], Multiple sclerosis, Male [MeSH], Multiple Sclerosis, Relapsing-Remitting/drug therapy [MeSH], Quality of Life [MeSH], Antibodies, Monoclonal, Humanized/pharmacology [MeSH], Anti-CD20 monoclonal antibody, Antibodies, Monoclonal, Humanized/adverse effects [MeSH], B-cell depletion, Follow-Up Studies
File Description: application/pdf
Access URL: https://pubmed.ncbi.nlm.nih.gov/39039273
https://hss-opus.ub.ruhr-uni-bochum.de/opus4/files/11750/KlimasRafael22072024.pdf
https://hss-opus.ub.ruhr-uni-bochum.de/opus4/frontdoor/index/index/docId/11750
https://nbn-resolving.org/urn:nbn:de:hbz:294-117508
https://repository.publisso.de/resource/frl:6493784 -
12
Authors: et al.
Source: Annals of oncology, vol. 36, no. 1, pp. 43-53
Subject Terms: Male, Aged, 80 and over, Adult, Arthritis, Humans, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/therapeutic use, Antibodies, Monoclonal, Humanized/adverse effects, Female, Immune Checkpoint Inhibitors/adverse effects, Immune Checkpoint Inhibitors/administration & dosage, Immune Checkpoint Inhibitors/therapeutic use, Retrospective Studies, Aged, Middle Aged, Arthritis/drug therapy, Prednisone/administration & dosage, Prednisone/therapeutic use, Neoplasms/drug therapy, Neoplasms/pathology, Recurrence, Secondary Prevention/methods, arthritis, immune checkpoint inhibitors, irAEs, secondary prophylaxis, tocilizumab, Antibodies, Monoclonal, Humanized, Neoplasms, Secondary Prevention, Prednisone, Immune Checkpoint Inhibitors
File Description: application/pdf
-
13
Authors: et al.
Contributors: et al.
Source: J Neurol
Journal of neurology, vol. 271, no. 8, pp. 5402-5410
Gantenbein, Andreas R; Bonvin, Christophe; Kamm, Christian P; Schankin, Christoph J; Zecca, Chiara; Zieglgänsberger, Dominik; Merki-Feld, Gabriele Susanne; Pohl, Heiko; Rudolph, Nicole; Ryvlin, Philippe; Agosti, Reto; Schäfer, Elisabeth; Meyer, Ina; Kulartz-Schank, Monika; Arzt, Michael E (2024). Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results. Journal of neurology, 271(8), pp. 5402-5410. Springer 10.1007/s00415-024-12470-6 <http://dx.doi.org/10.1007/s00415-024-12470-6>Subject Terms: Male, Adult, Original Communication, Migraine Disorders, 610 Medicine & health, Middle Aged, Antibodies, Monoclonal, Humanized, 10040 Clinic for Neurology, 3. Good health, Disability Evaluation, 2728 Neurology (clinical), Treatment Outcome, Calcitonin Gene-Related Peptide Receptor Antagonists, 2808 Neurology, Chronic Disease, Quality of Life, Humans, Female, Prospective Studies, Switzerland, Migraine Disorders/drug therapy, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/pharmacology, Calcitonin Gene-Related Peptide Receptor Antagonists/pharmacology, Calcitonin Gene-Related Peptide Receptor Antagonists/administration & dosage, Break, CGRP, Erenumab, Migraine, RWE, Real world evidence
File Description: application/pdf; ZORA_s00415_024_12470_6.pdf - application/pdf
-
14
Authors: et al.
Contributors: et al.
Source: Nat Med
Subject Terms: Male, Neoplasm, Residual, Humanized / adverse effects, MESH: Bortezomib* / therapeutic use, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Lenalidomide* / administration & dosage, Antibodies, Monoclonal, Humanized, Article, Dexamethasone, MESH: Neoplasm, Bortezomib, 03 medical and health sciences, 0302 clinical medicine, Humanized / administration & dosage, [SDV.CAN] Life Sciences [q-bio]/Cancer, MESH: Bortezomib* / administration & dosage, Monoclonal, Humanized / therapeutic use, Antineoplastic Combined Chemotherapy Protocols, MESH: Lenalidomide* / therapeutic use, MESH: Multiple Myeloma* / drug therapy, Humans, Lenalidomide, MESH: Treatment Outcome, Aged, MESH: Aged, MESH: Humans, MESH: Antibodies, MESH: Multiple Myeloma* / pathology, MESH: Male, 3. Good health, Treatment Outcome, Residual, MESH: Antineoplastic Combined Chemotherapy Protocols* / therapeutic use, MESH: Dexamethasone* / administration & dosage, Female, Multiple Myeloma, MESH: Female, MESH: Dexamethasone* / therapeutic use
File Description: application/pdf
-
15
Authors: et al.
Source: Novak, F, Bajwa, H M, Østergaard, K, Berg, J M, Madsen, J S, Olsen, D A, Urbonaviciute, I, Illes, Z, Stilund, M L, Romme Christensen, J, Bramow, S, Sellebjerg, F & Sejbaek, T 2024, 'Extended interval dosing with ocrelizumab in multiple sclerosis', Multiple Sclerosis Journal, vol. 30, no. 7, pp. 847–856. https://doi.org/10.1177/13524585241245296
Novak, F, Bajwa, H M, Østergaard, K, Berg, J M, Madsen, J S, Olsen, D A, Urbonaviciute, I, Illes, Z, Stilund, M L, Romme Christensen, J, Bramow, S, Sellebjerg, F & Sejbaek, T 2024, 'Extended interval dosing with ocrelizumab in multiple sclerosis', Multiple Sclerosis Journal, vol. 30, no. 7, pp. 847-856. https://doi.org/10.1177/13524585241245296Subject Terms: Male, Adult, Multiple Sclerosis, Antibodies, Monoclonal, Humanized, Antibodies, Drug Administration Schedule, Multiple sclerosis, 03 medical and health sciences, Multiple Sclerosis, Relapsing-Remitting, 0302 clinical medicine, ocrelizumab, treatment interval, Monoclonal, Humans, Immunologic Factors, Prospective Studies, neuroimaging, biomarkers, personalized medicine, Middle Aged, 16. Peace & justice, extended dosing, Magnetic Resonance Imaging, 3. Good health, Treatment Outcome, Humanized/administration & dosage, Multiple Sclerosis/drug therapy, Female, anti-CD20, Biomarkers/blood, Immunologic Factors/administration & dosage, NEDA-3, Biomarkers, Relapsing-Remitting/drug therapy
Access URL: https://pubmed.ncbi.nlm.nih.gov/38646949
https://vbn.aau.dk/da/publications/5d51f681-3ccb-4a3b-97f6-e70772223a45
http://www.scopus.com/inward/record.url?scp=85192384800&partnerID=8YFLogxK
https://doi.org/10.1177/13524585241245296
https://portal.findresearcher.sdu.dk/da/publications/1ca74460-bb93-4cf6-8413-10ba9385ec59
https://doi.org/10.1177/13524585241245296
http://www.scopus.com/inward/record.url?scp=85192384800&partnerID=8YFLogxK
https://doi.org/10.1177/13524585241245296
https://pure.au.dk/portal/en/publications/8814d2f2-bcc2-4bb6-aedf-9049223fec10 -
16
Authors: et al.
Contributors: et al.
Source: J Neurol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Hartung, H-P, Berger, T, Bermel, R A, Brochet, B, Carroll, W M, Holmøy, T, Karabudak, R, Killestein, J, Nos, C, Patti, F, Perrin Ross, A, Vanopdenbosch, L, Vollmer, T, Buffels, R, Garas, M, Kadner, K, Manfrini, M, Wang, Q & Freedman, M S 2024, 'ENSEMBLE PLUS : final results of shorter ocrelizumab infusion from a randomized controlled trial', Journal of Neurology, vol. 271, no. 7, pp. 4348-4360. https://doi.org/10.1007/s00415-024-12326-zSubject Terms: Male, Adult, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados, Phase 3, Antibodies, Monoclonal, Humanized, Infusion-related reaction, Teràpia intravenosa, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::vías de administración de medicamentos::administración intravenosa::infusiones intravenosas, Multiple Sclerosis, Relapsing-Remitting, Double-Blind Method, Humans, Immunologic Factors, Ocrelizumab, Infusions, Intravenous, DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis::Multiple Sclerosis, Relapsing-Remitting, Double-Blind Method [MeSH], Female [MeSH], Immunologic Factors/administration, Adult [MeSH], Humans [MeSH], Antibodies, Monoclonal, Humanized/administration, Infusions, Intravenous [MeSH], Middle Aged [MeSH], Male [MeSH], Multiple Sclerosis, Relapsing-Remitting/drug therapy [MeSH], Immunologic Factors/adverse effects [MeSH], Relapsing–remitting multiple sclerosis, Antibodies, Monoclonal, Humanized/adverse effects [MeSH], Shorter infusion, Original Communication, ENSEMBLE PLUS, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Anticossos monoclonals - Ús terapèutic, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, Middle Aged, 3. Good health, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, Avaluació de resultats (Assistència sanitària), Female, ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple::esclerosis múltiple recurrente-remitente, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Drug Administration Routes::Administration, Intravenous::Infusions, Intravenous, Esclerosi múltiple - Tractament
File Description: application/pdf
Access URL: https://pubmed.ncbi.nlm.nih.gov/38649522
https://hdl.handle.net/11351/11721
https://research.vumc.nl/en/publications/e6b23e9d-4ec9-49fb-b20f-f7ffe1bc3a43
https://pure.amsterdamumc.nl/en/publications/fc0bc14b-4e80-4a24-bdcb-c5d3f587937c
https://doi.org/10.1007/s00415-024-12326-z
https://repository.publisso.de/resource/frl:6518793 -
17
Authors: et al.
Source: Neurol Sci
Subject Terms: Review Article, Lecanemab, Alzheimer's disease, Monoclonal antibody, Adverse events, Amyloid-beta plaques, Alzheimer Disease, Humans, Antibodies, Monoclonal, Humanized, Randomized Controlled Trials as Topic [MeSH], Antibodies, Monoclonal, Humanized/therapeutic use [MeSH], Humans [MeSH], Alzheimer Disease/drug therapy [MeSH], Antibodies, Monoclonal, Humanized/administration, Antibodies, Monoclonal, Humanized/adverse effects [MeSH], ddc, Randomized Controlled Trials as Topic, 3. Good health
File Description: application/pdf
-
18
Authors: et al.
Contributors: et al.
Source: Oncologist
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
The oncologist, vol. 30, no. 3
Oncologist, vol 30, iss 3Subject Terms: Male, Adult, Carcinoma, Hepatocellular, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms, Medicaments antineoplàstics - Ús terapèutic, Antineoplastic Agents, DISEASES::Neoplasms::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms::Carcinoma, Hepatocellular, Herpesvirus 1, Human, Antibodies, Monoclonal, Humanized, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias hepáticas, Antibodies, Antineoplastic Agents, Immunological, ENFERMEDADES::neoplasias::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias hepáticas::carcinoma hepatocelular, COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica, Monoclonal, CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Immunological, 80 and over, Humans, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Oncolytic Virotherapy, Liver Neoplasms/drug therapy, Liver Neoplasms/pathology, Liver Neoplasms/secondary, Carcinoma, Hepatocellular/drug therapy, Carcinoma, Hepatocellular/pathology, Antibodies, Monoclonal, Humanized/therapeutic use, Antibodies, Monoclonal, Humanized/pharmacology, Antibodies, Monoclonal, Humanized/administration & dosage, Female, Middle Aged, Aged, Biological Products/therapeutic use, Biological Products/pharmacology, Biological Products/administration & dosage, Antineoplastic Agents, Immunological/therapeutic use, hepatocellular carcinoma, liver metastasis, pembrolizumab, solid tumor, talimogene laherparepvec, Metàstasi hepàtica - Tractament, Humanized, Oncolytic Virotherapy, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::viroterapia oncolítica, Biological Products, Other subheadings::Other subheadings::Other subheadings::/drug therapy, Anticossos monoclonals - Ús terapèutic, Herpesvirus 1, Càncer - Tractament, Clinical Trial Results, Carcinoma, Liver Neoplasms, Hepatocellular, Immunological, Medicaments biològics - Ús terapèutic, Human
File Description: application/pdf
Access URL: https://pubmed.ncbi.nlm.nih.gov/40156118
http://hdl.handle.net/11351/13055
https://serval.unil.ch/resource/serval:BIB_14A3EF9C1C3C.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_14A3EF9C1C3C
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_14A3EF9C1C3C3
https://escholarship.org/content/qt9695q2r3/qt9695q2r3.pdf
https://escholarship.org/uc/item/9695q2r3 -
19
Authors: et al.
Contributors: et al.
Source: Dig Dis Sci
Subject Terms: Crohn's disease, Monoclonal antibody, Adult, Biologic, Injections, Subcutaneous, Remission Induction, Network Meta-Analysis, Antibodies, Monoclonal, Humanized, General medicine, internal medicine and other clinical medicine, Infliximab, Crohn Disease/drug therapy [MeSH], Maintenance Chemotherapy/methods [MeSH], Adult [MeSH], Humans [MeSH], Systematic review, Treatment Outcome [MeSH], Infliximab/administration, Antibodies, Monoclonal, Humanized/administration, Administration, Intravenous [MeSH], Injections, Subcutaneous [MeSH], Original Article, Randomized Controlled Trials as Topic [MeSH], Colitis, Ulcerative/drug therapy [MeSH], Network meta-analysis, Infliximab/therapeutic use [MeSH], Gastrointestinal Agents/therapeutic use [MeSH], Antibodies, Monoclonal, Humanized/therapeutic use [MeSH], Remission Induction [MeSH], Ulcerative colitis, Gastrointestinal Agents/administration, Maintenance Chemotherapy, Treatment Outcome, Gastrointestinal Agents, Crohn Disease, Humans, Colitis, Ulcerative, Administration, Intravenous, Randomized Controlled Trials as Topic
File Description: application/pdf
-
20
Authors: et al.
Contributors: et al.
Source: New England Journal of Medicine. 390:911-921
Subject Terms: Adult, Granulomatosis with Polyangiitis/drug therapy, Churg-Strauss Syndrome/drug therapy, Eosinophils/drug effects, Anti-Inflammatory Agents/administration & dosage, Injections, Subcutaneous, Remission Induction, Glucocorticoids/adverse effects, Granulomatosis with Polyangiitis, Anti-Inflammatory Agents, Churg-Strauss Syndrome, Antibodies, Monoclonal, Humanized, 3. Good health, Eosinophils, Double-Blind Method, Recurrence, Interleukin-5 Receptor alpha Subunit, Chronic Disease, Humans, chronic disease, Glucocorticoids, Antibodies, Monoclonal, Humanized/administration & dosage, Interleukin-5 Receptor alpha Subunit/antagonists & inhibitors
Access URL: https://pubmed.ncbi.nlm.nih.gov/38393328
https://biblio.vub.ac.be/vubir/benralizumab-versus-mepolizumab-for-eosinophilic-granulomatosis-with-polyangiitis(9ad2e672-0a76-4a35-986d-b3491ec2bbc2).html
Full Text Finder 
Nájsť tento článok vo Web of Science 
Full Text